GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (FRA:PHPN) » Definitions » E10

Galectin Therapeutics (FRA:PHPN) E10 : €-0.63 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Galectin Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Galectin Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was €-0.147. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.63 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 3.00% per year. During the past 5 years, the average E10 Growth Rate was 4.50% per year. During the past 10 years, the average E10 Growth Rate was 5.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Galectin Therapeutics was 7.90% per year. The lowest was 2.80% per year. And the median was 6.15% per year.

As of today (2024-04-29), Galectin Therapeutics's current stock price is €3.22. Galectin Therapeutics's E10 for the quarter that ended in Dec. 2023 was €-0.63. Galectin Therapeutics's Shiller PE Ratio of today is .


Galectin Therapeutics E10 Historical Data

The historical data trend for Galectin Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics E10 Chart

Galectin Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.76 -0.64 -0.70 -0.74 -0.63

Galectin Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.74 -0.72 -0.64 -0.66 -0.63

Competitive Comparison of Galectin Therapeutics's E10

For the Biotechnology subindustry, Galectin Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galectin Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Shiller PE Ratio falls into.



Galectin Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Galectin Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.147/129.4194*129.4194
=-0.147

Current CPI (Dec. 2023) = 129.4194.

Galectin Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 -0.195 99.695 -0.253
201406 -0.125 100.560 -0.161
201409 -0.132 100.428 -0.170
201412 -0.146 99.070 -0.191
201503 -0.203 99.621 -0.264
201506 -0.187 100.684 -0.240
201509 -0.232 100.392 -0.299
201512 -0.174 99.792 -0.226
201603 -0.216 100.470 -0.278
201606 -0.178 101.688 -0.227
201609 -0.143 101.861 -0.182
201612 -0.152 101.863 -0.193
201703 -0.140 102.862 -0.176
201706 -0.125 103.349 -0.157
201709 -0.109 104.136 -0.135
201712 -0.059 104.011 -0.073
201803 -0.097 105.290 -0.119
201806 -0.094 106.317 -0.114
201809 -0.060 106.507 -0.073
201812 -0.070 105.998 -0.085
201903 -0.177 107.251 -0.214
201906 -0.053 108.070 -0.063
201909 -0.045 108.329 -0.054
201912 -0.108 108.420 -0.129
202003 -0.054 108.902 -0.064
202006 -0.098 108.767 -0.117
202009 -0.085 109.815 -0.100
202012 -0.107 109.897 -0.126
202103 -0.092 111.754 -0.107
202106 -0.125 114.631 -0.141
202109 -0.119 115.734 -0.133
202112 -0.106 117.630 -0.117
202203 -0.154 121.301 -0.164
202206 -0.151 125.017 -0.156
202209 -0.141 125.227 -0.146
202212 -0.170 125.222 -0.176
202303 -0.177 127.348 -0.180
202306 -0.138 128.729 -0.139
202309 -0.225 129.860 -0.224
202312 -0.147 129.419 -0.147

Add all the adjusted EPS together and divide 10 will get our e10.


Galectin Therapeutics  (FRA:PHPN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Galectin Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Galectin Therapeutics (FRA:PHPN) Business Description

Traded in Other Exchanges
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics (FRA:PHPN) Headlines

No Headlines